PARIS (Agefi-Dow Jones)–The pharmaceutical group Ipsen on Tuesday announced the results of analyzes of the phase 3 CheckMate -9ER study, which demonstrated sustained benefits in terms of survival and response rates for its drug Cabometyx. , in combination with Opdivo from its American counterpart Bristol-Myers Squibb, in the first-line treatment of advanced renal cell carcinoma.
“Over a median follow-up period of 32.9 months (minimum 25.4 months), Cabometyx in combination with Opdivo continued to demonstrate clinical superiority for efficacy endpoints, in terms of overall survival, progression-free survival, objective response rate and disease control rate, including increased complete response rates compared to sunitinib,” Ipsen said in a statement.
Sunitinib is a drug for the treatment of advanced kidney cancer developed by the American pharmaceutical company Pfizer and marketed under the name Sutent.
Cabometyx is notably approved in the United States and the European Union for the treatment of advanced renal cell carcinoma, of which more than 400,000 new cases were diagnosed worldwide in 2020. Cabometyx is a registered trademark of the American biotech Exelixis, for which Ipsen has exclusive marketing rights outside the United States and Japan.
-Dimitri Delmond, Agefi-Dow Jones; +33 (0)1 41 27 47 31; [email protected] ed: JXM
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
February 15, 2022 01:36 ET (06:36 GMT)